Comparison of different 2D muscle indexes measured at the level of the 3rd lumbar vertebra in survival prediction in patients with renal cell carcinoma
DOI:
https://doi.org/10.2340/1651-226X.2024.27450Keywords:
renal cell carcinoma, sarcopenia, muscle index, body compositionAbstract
Background: Low computed tomography (CT)-determined muscle mass, commonly determined with height-adjusted muscle indexes (MIs), predicts worse survival in several cancers and has been suggested as a prognostic assessment tool. Although several MIs measured at the level of the 3rd lumbar vertebra (L3) are commonly used, it remains unestablished how different L3-determined MIs perform in survival prognostication compared to each other. The objective of this study was to investigate the performance of different MIs for survival prognostication in renal cell carcinoma (RCC).
Methods: We retrospectively enrolled 214 consecutive patients with RCC. We determined three L3-MIs (psoas muscle index (PMI), psoas muscle index and erector spinae index (PMI+ESI), and whole skeletal muscle index (SMI)) from preoperative CT scans. Categorization of those with low and normal muscle mass was based on the Youden Index sex-specific MI cut-offs. We determined sensitivity, specificity, and accuracy metrics for predicting 1-year, 5-year, and overall survival (OS) using Cox regression models.
Results: Low PMI, PMI+ESI, and SMI significantly predicted decreased 1-year, 5-year, and OS in uni- and multivariate models. PMI+ESI and SMI were more accurate than PMI in males, and PMI and PMI+ESI were more accurate than SMI in females in the prediction of 1-year survival. However, there were no differences in accuracies between MIs in 5-year and OS prediction.
Interpretation: PMI+ESI performed well overall in short-term prognostication, but there were no differences between the MIs in long-term prognostication. We recommend the use of PMI+ESI for muscle evaluation, particularly when SMI cannot be evaluated.
Downloads
References
Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3(1):17009.
https://doi.org/10.1038/nrdp.2017.9 DOI: https://doi.org/10.1038/nrdp.2017.9
Makino T, Kadomoto S, Izumi K, et al. Epidemiology and prevention of renal cell carcino-ma. Cancers. 2022;14(16):4059.
https://doi.org/10.3390/cancers14164059 DOI: https://doi.org/10.3390/cancers14164059
Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87.
https://doi.org/10.14740/wjon1279 DOI: https://doi.org/10.14740/wjon1279
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. 2020;70(1):7–30.
https://doi.org/10.3322/caac.21590 DOI: https://doi.org/10.3322/caac.21590
Wilkinson DJ, Piasecki M, Atherton PJ. The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atro-phy and muscle fibre loss in humans. Ageing Res Rev. 2018 Nov;47:123–32.
https://doi.org/10.1016/j.arr.2018.07.005 DOI: https://doi.org/10.1016/j.arr.2018.07.005
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the extended group for EWGSOP2. Sarcopenia: revised European consen-sus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16–31.
https://doi.org/10.1093/ageing/afy169 DOI: https://doi.org/10.1093/ageing/afy169
Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019 Jun 29;393(10191):2636–46. DOI: https://doi.org/10.1016/S0140-6736(19)31138-9
https://doi.org/10.1016/S0140-6736(19)31138-9. Erratum in: Lancet. 2019 Jun 29;393(10191):2590. DOI: https://doi.org/10.1016/S0140-6736(19)31474-6
Petermann-Rocha F, Pell JP, Celis-Morales C, et al. Frailty, sarcopenia, cachexia and mal-nutrition as comorbid conditions and their associations with mortality: a prospective study from UK Biobank. J Public Health. 2022;44(2):e172–80.
https://doi.org/10.1093/pubmed/fdaa226 DOI: https://doi.org/10.1093/pubmed/fdaa226
Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independ-ent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539–47.
https://doi.org/10.1200/JCO.2012.45.2722 DOI: https://doi.org/10.1200/JCO.2012.45.2722
Tolonen A, Pakarinen T, Sassi A, et al. Methodology, clinical applications, and future di-rections of body composition analysis using computed to-mography (CT) images: a review. Eur J Radiol. 2021;145:109943.
https://doi.org/10.1016/j.ejrad.2021.109943 DOI: https://doi.org/10.1016/j.ejrad.2021.109943
Nipp RD, Fuchs G, El-Jawahri A, et al. Sarcopenia is associated with quality of life and de-pression in patients with advanced cancer. Oncologist. 2018 Jan;23(1):97–104.
https://doi.org/10.1634/theoncologist.2017-0255 DOI: https://doi.org/10.1634/theoncologist.2017-0255
Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019 Jan;8(1):86–101.
https://doi.org/10.21037/apm.2018.08.02 DOI: https://doi.org/10.21037/apm.2018.08.02
Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017 Sep 1;28(9):2107–18.
https://doi.org/10.1093/annonc/mdx271 DOI: https://doi.org/10.1093/annonc/mdx271
McGovern J, Dolan RD, Horgan PG, et al. Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle. 2021;12(6):1408–17.
https://doi.org/10.1002/jcsm.12831 DOI: https://doi.org/10.1002/jcsm.12831
Surov A, Wienke A. Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients. JPEN J Parenter Enteral Nutr. 2022 Nov;46(8):1761–8.
https://doi.org/10.1002/jpen.2415 DOI: https://doi.org/10.1002/jpen.2415
Yuxuan L, Junchao L, Wenya L. The role of sarcopenia in treatment-related outcomes in patients with renal cell carcinoma: a systematic review and meta-analysis. Medicine. 2022;101(43):e31332.
https://doi.org/10.1097/MD.0000000000031332 DOI: https://doi.org/10.1097/MD.0000000000031332
Tolonen A, Kerminen H, Lehtomäki K, et al. Association between computed tomography-determined loss of muscle mass and impaired three-month survival in frail older adults with cancer. Cancers. 2023;15(13):3398.
https://doi.org/10.3390/cancers15133398 DOI: https://doi.org/10.3390/cancers15133398
Higgins MI, Martini DJ, Patil DH, et al. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carci-noma. Cancer. 2021;127(12):1974–83.
https://doi.org/10.1002/cncr.33462 DOI: https://doi.org/10.1002/cncr.33462
Lee J, Suh J, Song C, et al. Association between sarcopenia and survival of patients with organ-confined renal cell carcinoma after radical nephrec-tomy. Ann Surg Oncol. 2022;29(4):2473–9.
https://doi.org/10.1245/s10434-021-10881-7 DOI: https://doi.org/10.1245/s10434-021-10881-7
Midenberg E, Higgins MI, Schmeusser BN, et al. Prognostic value of sarcopenia and al-bumin in the surgical management of localized renal cell car-cinoma. Urol Oncol. 2023 Jan;41(1):50.e19–50.e26.
https://doi.org/10.1016/j.urolonc.2022.09.020 DOI: https://doi.org/10.1016/j.urolonc.2022.09.020
Fukushima H, Nakanishi Y, Kataoka M, et al. Prognostic significance of sarcopenia in pa-tients with metastatic renal cell carcinoma. J Urol. 2016 Jan;195(1):26–32.
https://doi.org/10.1016/j.juro.2015.08.071 DOI: https://doi.org/10.1016/j.juro.2015.08.071
Sharma P, Zargar-Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug;33(8):339.e17–23.
https://doi.org/10.1016/j.urolonc.2015.01.011 DOI: https://doi.org/10.1016/j.urolonc.2015.01.011
Ueki H, Hara T, Okamura Y, et al. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: a retrospective study. Investig Clin Urol. 2022 Jul;63(4):415–24.
https://doi.org/10.4111/icu.20220028. DOI: https://doi.org/10.4111/icu.20220028
Peyton CC, Heavner MG, Rague JT, et al. Does sarcopenia impact complications and over-all survival in patients undergoing radical nephrectomy for stage III and IV kidney cancer? J Endourol. 2016 Feb;30(2):229–36.
https://doi.org/10.1089/end.2015.0492 DOI: https://doi.org/10.1089/end.2015.0492
Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010 Aug;21(8):1594–8.
https://doi.org/10.1093/annonc/mdp605 DOI: https://doi.org/10.1093/annonc/mdp605
Lee CH, Ku JY, Seo WI, et al. Prognostic significance of sarcopenia and decreased relative dose intensity during the initial two cycles of first-line sunitinib for metastatic renal cell carcinoma. J Chemother. 2021 Jul;33(4):245–55.
https://doi.org/10.1080/1120009X.2020.1866825 DOI: https://doi.org/10.1080/1120009X.2020.1866825
Albano D, Messina C, Vitale J, et al. Imaging of sarcopenia: old evidence and new insights. Eur Radiol. 2020;30(4):2199–208.
https://doi.org/10.1007/s00330-019-06573-2 DOI: https://doi.org/10.1007/s00330-019-06573-2
Antoun S, Rossoni C, Lanoy E. What’s next in using CT scans to better understand ca-chexia? Curr Opin Support Palliat Care. 2018;12(4):427–33.
https://doi.org/10.1097/SPC.0000000000000388 DOI: https://doi.org/10.1097/SPC.0000000000000388
Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3):2022-vol3.
Ebadi M, Wang CW, Lai JC, et al. Poor performance of psoas muscle index for identifica-tion of patients with higher waitlist mortality risk in cirrhosis. J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1053–62.
https://doi.org/10.1002/jcsm.12349 DOI: https://doi.org/10.1002/jcsm.12349
Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):630–8.
https://doi.org/10.1002/jcsm.12180 DOI: https://doi.org/10.1002/jcsm.12180
Baratloo A, Hosseini M, Negida A, et al. Part 1: simple definition and calculation of accu-racy, sensitivity and specificity. Emerg (Tehran). 2015;3(2):48–9.
Van Den Broeck J, Sealy MJ, Brussaard C, et al. The correlation of muscle quantity and quality between all vertebra levels and level L3, measured with CT: an exploratory study. Front Nutr. 2023 Feb 23;10:1148809.
https://doi.org/10.3389/fnut.2023.1148809 DOI: https://doi.org/10.3389/fnut.2023.1148809
Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016 Apr;57:58–67.
https://doi.org/10.1016/j.ejca.2015.12.030 DOI: https://doi.org/10.1016/j.ejca.2015.12.030
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6–10.
https://doi.org/10.1016/j.metabol.2018.09.005 DOI: https://doi.org/10.1016/j.metabol.2018.09.005
Smith-Bindman R, Kwan ML, Marlow EC, et al. Trends in use of medical imaging in US health care systems and in Ontario, Canada, 2000–2016. JAMA. 2019 Sep 3;322(9):843–56.
https://doi.org/10.1001/jama.2019.11456 DOI: https://doi.org/10.1001/jama.2019.11456
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Oona Janhunen, Otto Jokelainen, Robin Peltoniemi, Timo K. Nykopp, Otso Arponen
This work is licensed under a Creative Commons Attribution 4.0 International License.
